Immunome (IMNM) Stock Price, Quote, News & History | Benzinga

Immunome Inc (IMNM) Stock Price, Quote, News & History

IMNMNASDAQ

Trade with Public

Trade with Public

$27.20

0.782.95%

At close: Aug 14, 5:00 PM EST

$27.14

-0.06-0.22%

After Hours: 6:39 PM EST

Earnings: Q2 2026 Earnings were released on Tue Aug 11th, after the market close

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$26.38

Close

$27.20

Volume / Avg.

760.76K / 1.38M

Day Range

$25.59 - $27.30

52 Wk Range

8.66 - 28.62

Market Cap

$3.08B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

66

Short Interest

18.51%

Days to Cover

22.98

Recent Immunome, Inc. News

SpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

U.S. stock futures mixed, Dow up 100 points. SpaceX stock falls 10.3% after reporting strong Q2 revenue but a loss. Other stocks also decline.

Avi Kapoor

Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review

FDA accepts Immunome's varegacestat NDA for desmoid tumors, with an April 28, 2027, PDUFA date backed by positive Phase 3 data.

Vandana Singh

This Sezzle Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Avi Kapoor

The Insider Report: Batten Down the Hatches

Gianni di Poce

What's Going On With Immunome Shares Monday?

Immunome shares trade higher on Monday after the company announced results from the global pivotal Phase 3 RINGSIDE trial of varegcasetat and met its primary endpoint.

Dylan Berman

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-208.79M

Investing Cash Flow (TTM)

-196.48M

Financing Cash Flow (TTM)

479.11M

Free Cash Flow (TTM)

-228.10M

Capital Expenditure (TTM)

-19.31M

Net Change in Cash (TTM)

73.83M

Analyst Trends and Forecast

2

Mar

4

May

1

Jun

1

Jul

2

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.58B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

5.71

Earnings Yield % (TTM)

-9.58%

Earnings Yield % (FWD)

-9.27%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$4.62

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$217.71M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$26.38

Close

$27.20

Volume / Avg.

760.76K / 1.38M

Day Range

$25.59 - $27.30

52 Wk Range

8.66 - 28.62

Market Cap

$3.08B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

66

Short Interest

18.51%

Days to Cover

22.98

About

Sector

Health Care

Industry

Biotechnology

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncolo...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Immunome (IMNM) stock?

A

You can purchase shares of Immunome (NASDAQ:IMNM) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Immunome (IMNM) competitors?

A

Other companies in Immunome’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Immunome (IMNM) stock?

A

Immunome has a consensus price target of $32.00.

Q

What is the current price for Immunome (IMNM)?

A

The stock price for Immunome (NASDAQ: IMNM) is $27.14 last updated August 14, 2026 at 6:39 PM EDT.

Q

Does Immunome (IMNM) pay a dividend?

A

There are no upcoming dividends for Immunome.

Q

When is Immunome (NASDAQ:IMNM) reporting earnings?

A

Immunome does not have any upcoming earnings scheduled.

Q

Is Immunome (IMNM) going to split?

A

There is no upcoming split for Immunome.

Q

What sector and industry does Immunome (IMNM) operate in?

A

Immunome is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.